The federal government’s April 2026 partial rescheduling of marijuana—placing FDA-approved products and marijuana subject to a qualifying state-issued medical marijuana license into Schedule III while leaving most adult-use marijuana in Schedule I—has created new conformity pressures for mature medical cannabis states.¹ South Dakota illustrates one variant of this federalism challenge. Unlike states with a single … Continue reading The South Dakota Board of Pharmacy and the April 2026 Federal Partial Rescheduling: An Implementing Role in a Layered Statutory Framework